This past February, practitioners and leading oncologists from around the world gathered for the second annual Practical Recommendations in Immuno and Molecular Oncology (PRIMO) meeting, in order to learn and discuss the latest updates and trials in the field of oncology. Our Co-Chairs and Steering Committee worked diligently to create an expansive agenda focusing on the latest targeted and immuno therapies across multiple tumors, such as melanoma, head and neck cancer, lung cancer, gastrointestinal malignancies, hematologic malignancies, as well as the future of cancer prevention.
Following the conference’s continued success, PRIMO is excited to announce the upcoming dates for the 2018 meeting. The third annual meeting will take place from January 31 to February 3—a perfect time to start the year off with a recap of the latest breakthroughs!
PRIMO is also pleased to announce the Steering Committee and Co-Chairs for next year’s meeting. The Co-Chairs include:
Julie Brahmer, MD, Director, Thoracic Oncology Program, Associate Professor of Oncology, Sidney Kimmel Comprehensive Career Center, Johns Hopkins Medicine, Baltimore, Maryland;
Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor, Chief, Division of Hematology/Oncology, Professor of Medicine, Nebraska Medical Center, Omaha, Nebraska;
Hope S. Rugo, MD, Professor of Medicine, Director, Breast Oncology and Clinical Trials Education, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
The Steering Committee members are:
Sanjiv Agarwala, MD, Professor of Medicine, Chief, Oncology and Hematology, St. Luke’s University Hospital, and Temple University, Philadelphia, Pennsylvania;
Charles Balch, MD, PhD, Professor of Surgical Oncology, University of Texas, Southwestern Medical Center, Dallas Texas;
Sagar Lonial, MD, Professor, Department of Hematology and Medical Oncology, Chief Medical Officer, Winship Cancer Institute, Emory University, Atlanta, Georgia;
Alan P. Venook, MD, Professor of Medicine, Shorenstein Associate Director for Program Development, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
The elected members have evaluated and analyzed the past two meetings to deliver attendees a substantial and extensive agenda for 2018, packed with the most important and compelling subjects related to immuno and molecular oncology.
To learn more about our faculty, agenda, and highlights from past meetings, you can click here.
There is now a discount for early registration, so be sure to take advantage of this great offer before August 1! You can register by clicking here.